{
  "id": 6595298,
  "title": "FDA places partial hold on Biohaven's ion channel drug",
  "url": "https://urgent.news/2026/09/10/fda-places-partial-hold-on-biohavens-ion-channel-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-10T13:58:04.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-places-partial-hold-on-biohavens-ion-channel-drug/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA has placed a troubled Biohaven program on partial clinical hold, the company disclosed Wednesday. An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "FDA places partial hold on Biohaven’s epilepsy drug",
        "url": "https://urgent.news/2026/09/10/fda-places-partial-hold-on-biohavens-epilepsy-drug",
        "published": "2026-09-10T16:13:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}